SCHEMBL564345

SCHEMBL564345

CCC(C(N)=O)N1CC(c2ccc(Cl)c(Cl)c2)CC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 10/20 0.40
SLC6A3 Q01959 10/20 0.40
SLC6A2 P23975 7/20 0.40
LMNA P02545 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA3 P07451 1/20 0.40
CA4 P22748 1/20 0.40
CA6 P23280 1/20 0.40
CA5A P35218 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA13 Q8N1Q1 1/20 0.40
CA14 Q9ULX7 1/20 0.40
CA5B Q9Y2D0 1/20 0.40
PDE4A P27815 3/20 0.39
PDE4B Q07343 3/20 0.39
PDE4C Q08493 3/20 0.39
PDE4D Q08499 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL564124 0.86 LMNA (0.43) LMNACA12CA1CA2CA3
SCHEMBL564465 0.85 MDM2 (0.44) LMNACA12CA1CA2CA3
SCHEMBL563943 0.83 LMNA (0.43) LMNACA12CA1CA2CA3
SCHEMBL563778 0.83 LMNA (0.43) LMNACA12CA1CA2CA3
SCHEMBL563773 0.82 SLC6A4 (0.41) SLC6A4SLC6A3SLC6A2LMNACA12
SCHEMBL10239542 0.81 BRD4 (0.50) LMNACA12CA1CA2CA3
SCHEMBL564216 0.81 BRD4 (0.50) LMNACA12CA1CA2CA3
SCHEMBL563294 0.81 LMNA (0.40) SLC6A4SLC6A3SLC6A2LMNACA12
SCHEMBL563451 0.81 LMNA (0.40) LMNACA12CA1CA2CA3
SCHEMBL563617 0.81 ALDH1A1 (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1265862-B1 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB SA (BE) 2005-09-21 EP claimed
US-6784197-B2 SUCH AS (2S)-2-((4S)-4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL) BUTANAMIDE; ANTIEPILEPTIC AGENTS; ANTICONVULSANTS UCB S.A. (BE) 2004-08-31 US claimed
US-20240293363-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2024-09-05 US disclosed
US-20230277501-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2023-09-07 US disclosed
US-20230033195-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2023-02-02 US disclosed
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2022-08-25 US disclosed
US-20220218665-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2022-07-14 US disclosed
US-11160785-B2 Methods and compositions for improving cognitive function AGENEBIO INC. (US) 2021-11-02 US disclosed
US-20210244709-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2021-08-12 US disclosed
EP-3827820-A1 BRIVARACETAM FOR IMPROVING COGNITIVE FUNCTION The Johns Hopkins University (US) 2021-06-02 EP disclosed
EP-3260118-B1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2021-03-24 EP disclosed
US-20100099735-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2010-04-22 US disclosed
WO-2010044878-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY (US) 2010-04-22 WO disclosed
US-7692028-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2010-04-06 US disclosed
US-20080097109-A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB BIOPHARMA SPRL (BE) 2008-04-24 US disclosed
WO-2006090275-A1 TREATMENT OF INCONTINENCE PFIZER LIMITED (GB) 2006-08-31 WO disclosed
US-20050171187-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses DIFFERDING EDMOND (BE) 2005-08-04 US disclosed
US-6911461-B2 For treating epilepsy, epileptogenesis, seizure disorders, convulsions, bipolar disorders, mania, depression, anxiety, migraine, neuralgia, chronic pain, neuropathic pain, cerebral ischemia, cardiac arrhythmia, myotonia, cocaine abuse UCB, S.A. (BE) 2005-06-28 US disclosed
US-6806287-B2 NEUROLOGICAL DISORDERS; SUCH AS 2-(4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL)BUTANAMIDE UCB, S.A. (BE) 2004-10-19 US disclosed
US-6784197-B2 SUCH AS (2S)-2-((4S)-4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL) BUTANAMIDE; ANTIEPILEPTIC AGENTS; ANTICONVULSANTS UCB S.A. (BE) 2004-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171187-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses CYP1B1, OGDH, CYP1A2 SLC6A4 3225/4885SLC6A3 2687/4885SLC6A2 2597/4885
US-20080097109-A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses CYP1B1, OGDH, CYP1A2 SLC6A4 3225/4885SLC6A3 2687/4885SLC6A2 2597/4885
US-20210244709-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2A, CHRNA2, SYNGR2 SLC6A4 485/4885SLC6A3 254/4885SLC6A2 81/4885
US-11160785-B2 Methods and compositions for improving cognitive function BACE2, BACE1, GRIN2A SLC6A4 699/4885SLC6A3 115/4885SLC6A2 50/4885
US-20100099735-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, RAB2A, VAMP8 SLC6A4 884/4885SLC6A3 1148/4885SLC6A2 139/4885
US-20240293363-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, RAB2A, VAMP8 SLC6A4 884/4885SLC6A3 1148/4885SLC6A2 139/4885
US-20220218665-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, RAB2A, VAMP8 SLC6A4 884/4885SLC6A3 1148/4885SLC6A2 139/4885
US-20230277501-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2A, CHRNA2, SYNGR2 SLC6A4 485/4885SLC6A3 254/4885SLC6A2 81/4885
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE SLC6A4 602/4885SLC6A3 299/4885SLC6A2 71/4885
US-20230033195-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2D, GRIN2A, SLC18A2 SLC6A4 772/4885SLC6A3 537/4885SLC6A2 72/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.